Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Abbott tops consensus expectations despite decline in COVID-19 testing related sales

Published 25/01/2023, 14:59
Updated 25/01/2023, 14:59
© Reuters.

© Reuters.

By Sam Boughedda

Abbott (NYSE:ABT) shares fell Wednesday despite topping consensus expectations for profit and revenue.

The medical device firm reported adjusted fourth-quarter earnings of $1.03 per share, $0.11 better than the analyst estimate of $0.92.

Revenue for the quarter came in at $10.1 billion versus the consensus estimate of $9.62B. Despite topping consensus estimates, the company said revenue fell 12% year-over-year, negatively impacted by an expected decline in COVID-19 testing-related sales.

"We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions," said Robert Ford, chairman and chief executive officer of Abbott. "Our R&D pipeline continues to be highly productive with several recent and upcoming new product launches that position us well going forward."

Looking forward, Abbott sees FY2023 EPS between $4.30 and $4.50, in line with the consensus estimate of $4.40.

Following the earnings release, Stifel analysts said there were few surprises.

"Abbott's Covid testing business once again helped deliver above-Consensus top and bottom-line performance, with 4Q22 sales at $10.1B beating Stifel/Consensus $9.45B/$9.6B projections," they said. "EPS at $1.03 was also ahead of Stifel/Consensus $0.88/$0.92. Our 4Q22 estimates incorporated $500M Covid test sales, while the company sold $1.069B...effectively the entire difference between our projections and Abbott top-line results."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.